Effect of Lactobacillus brevis (MG000874) on antioxidant-related gene expression of the liver and kidney in D-galactose-induced oxidative stress mice model.

Oxidative stress (OS) is a phenomenon induced by excessive production and accumulation of reactive oxygen species (ROS) in living cells. These increased ROS productions connected, coupled with many neurological and physiological diseases. Several antioxidants were utilized recently to combat OS, and lactic acid bacteria have a potent radical-scavenging activity to minimize OS. The present work was designed to find out the protective effects of Lactobacillus brevis MG000874 (L. brevis MG000874) against oxidative injuries induced by D-galactose (D-gal) in vivo and to explore the gene expression of OS-related gene mice. Sixty male mice were randomly split into six groups. The first four groups were different control groups as no treatment (N), positive (G), probiotic (B), and ascorbic acid (A); the remaining two groups were treatment groups such as probiotic treatment (BG) and ascorbic acid treatment (AG). L. brevis MG000874 (0.2 ml of 1010 CFU/ml) and ascorbic acid (0.2 ml of 25 mg/ml) were administered orally daily for 5 weeks. It was revealed that these significantly affect the weight of treated mice: 40.22 ± 1.5 and 33.0 ± 0.57 g on days 0 and 36, respectively. D-gal induction in mice declined the levels of SOD and CAT determined by spectrophotometer. Administration of L. brevis MG000874 improved the antioxidant status of the stress mice and recovered the antioxidant activities of SOD and CAT enzymes. In addition, L. brevis MG000874-altered gene expression of OS marker at the messenger RNA (mRNA) levels was determined by RT-PCR in the mouse model. L. brevis MG000874 significantly improved the GST, GPX, SOD, CAT, and ß-actin levels in the kidney and the liver of the D-gal-induced mice (p < 0.05). Moreover, the histological investigation indicated that L. brevis MG000874 mitigated damage to the kidney and liver effectively in mice induced by D-gal. Therefore, it could be concluded from the current results that L. brevis MG000874 may act as a powerful antioxidant agent, and this study can provide the baseline data for drug development against OS-linked diseases.

Antilisterial efficacy of Lactobacillus brevis MF179529 from cow: an in vivo evidence.

BACKGROUND: Listeria monocytogenes is an opportunistic foodborne pathogen that causes human Listeriosis and high mortality particularly in immunocompromised individuals. Pregnant women are more prone to L. monocytogenes infection resulting in abortions. In the present study, antilisterial activity of Lactobacillus brevis (LB) MF179529, a probiotic bacterial strain, was investigated in a murine model. METHODS: Initially a pilot study was conducted to determine the dose of L. monocytogenes required to cause symptomatic listeriosis. In the main trial, mice were divided into 4 groups. Group I was kept as negative control, group II was exposed to L. monocytogenes and maintained as positive control. Group III was fed with L. brevis only, while group IV received L. brevis for 3 days prior to L. monocytogenes infection. A volume of 200 µl of L. monocytogenes ATCC 19115 and L. brevis MF179529 bacterial suspension corresponding to cell density of 109CFU/ml were given to respective groups by intragastric route. Progress of infection was monitored for 7 days including general health scoring, listeria dispersion in organs, bacterial load in intestine and blood biochemistry were recorded on 3rd, 5th and 7th days post infection (dpi). RESULTS: Clinical listeriosis was induced by 109CFU/ml of L. monocytogenes ATCC 19115 in mice. Animals of group IV displayed minor signs of infection. L. brevis supplementation resulted in significant reduction in dispersion and propagation of L. monocytogenes in liver, spleen and intestine. L. brevis MF179529 consumption led to a significant elevation of number of lactic acid bacteria and reduction of total plate count, anaerobic count and coliform population in intestine. Moreover, total leukocyte and neutrophil counts of treated animals were similar to the negative control while positive control group displayed higher number. Safety evaluation of L. brevis was performed by monitoring general health, hematological and serological parameters of L. brevis fed and negative control group (group III and I). No significant difference in feed intake, body temperature, body weight and blood picture could be detected in L. brevis supplemented and control groups. CONCLUSION: Our results indicate ameliorative role of L. brevis in L. monocytogenes infection and suggest that L. brevis could be used for prophylactic measure.